Home > NEWS
Canagliflozin, a new sodium–glucose cotransporter 2 inhibitor, in the treatment of diabetes
release time:2020-10-12

API information:

Product name:Canpagliflozin         Cas No.:842133-18-0

Molecular Formula:C24H25FO5S      Molecular Weight:444.51600

Structure:

Key intermediates information:

Product name:

(3R,4S,5R,6R)-3,4,5-tris(triMethylsilyloxy)-6-((triMethylsilyloxy)Methyl)tetrahydro-2H-pyran-2-one      

Cas No.:32384-65-9

Molecular Formula:C18H42O6Si4      Molecular Weight:466.86448

Structure:

Product name:2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene      

Cas No.:1030825-20-7

Molecular Formula:C18H14BrFS      Molecular Weight:361.2711632

Structure:

Product name:

D-Glucopyranoside,Methyl 1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-      

Cas No.:1030825-21-8

Molecular Formula:C25H27FO6S      Molecular Weight:474.5416832

Structure:

Product name:

D-Glucitol, 1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]Methyl]-4-Methylphenyl]-, tetraacetate, (1S)- (9CI)

Cas No.:866607-35-4

Molecular Formula:C32H33FO9S      Molecular Weight:612.6624232

Structure:

.................................................................................................................................................................................................

Canagliflozin belongs to a class of agents—the sodium–glucose co-transporter 2 (SGLT2) inhibitors—whose novel mechanism of action offers potential advantages over other antihyperglycemic agents, including a relatively low hypoglycemia risk and weight loss-promoting effects. Canagliflozin has dose-dependent pharmacokinetics, and research in laboratory animals demonstrated high oral bioavailability (85%) and rapid effects in lowering glycosylated hemoglobin (HbA1c) values. In four early-stage clinical trials involving a total of over 500 patients, the use of canagliflozin for varying periods was associated with significant mean reductions in HbA1c (absolute reductions of 0.45–0.92%) and fasting plasma glucose (decreases ranged from 16.2% to 42.4%) and weight loss ranging from 0.7 to 3.5 kg.


.................................................................................................................................................................................................

As Anti-diabetes series drug,Canagliflozin is similar as its brother drug-Empagliflozin.Canagliflozin and Empagliflozin can reduce the incidence of major cardiovascular events and have a good protective effect on the kidney.

The capacity of Canpagliflozin API is 600-800kg/month with Facility GMP and DMF is being working.


Headquarter Office in ShenZhen, R&D center in HangZhou, GMP factory in JiangSu.


Please note:All products which might have patent infringment are used for R&D only/ It's Not Senova's responsibility in those markets where there are patent infringement regulated.)

PLANT:



WORKSHOP:



R&D ROOM:


WAREHOUSE:


PACKING:


COA:

..................................................................................................................................................................................................

SENOVA:


Senova means“Step For Innovation", we are a professional company who's supplying APIs(mainly New Generics), Advanced Intermediates and KSM(Key Starting Materials) as well as technical Support/Registration support/Custom synthesis service in pharmaceutical and related field , we focus on serving those manufacturers' New Generics Projects from R&D stage to Commercial Stage from meterials to documents support(DMF/CMC). For those regulated markets, we secure all of our products can be produced under GMP regulation with Full Documentation.





Copyright Copyright (C) 2015-2035 Senova Technology Co. Ltd.
Address: 311# in Building 3 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055  Tel: +86-0755-8670 3119 QQ: 530953397